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Electronic Supplementary Material (ESI) for MedChemComm. This journal is © The Royal Society of Chemistry 2017 n/a n/a n/a 121 n/a n/a n/a 122 n/a n/a n/a 123 n/a n/a n/a 124 n/a n/a n/a 125 n/a n/a n/a 126 n/a n/a n/a 127 n/a n/a n/ a Inhibition assays were carried out under standard conditions. LgtC, MnCl 2 (5 mM), chicken egg-white lysozyme (CEL, 1 mg/mL), calf-intestinal phosphatase (CIP, 10 U/mL), Triton X-100 (0.01%), and HEPES buffer (13 mM, pH 7.0) were combined with β-lactose acceptor (2 mM) or buffer (control). Inhibitor (0-100 µM) in DMSO or DMSO only (15 µL, control) was added. The reaction was started by addition of UDP-Gal donor (28 µM) and incubated for 20 mins at 30°C. Malachite Green reagent A was added, and the microplate was shaken carefully. Malachite Green reagent B was added, and the absorbance was recorded at 620 nm. Data were analysed with GraphPad Prism. The 96-well plate experiment was carried out in triplicate. 118.4, 124.7, 127.1, 128.8, 128.9, 131.8, 135.3, 137.9, 138.0, 146.7, 151.8, 161.4 (Z)-4-(2-Chlorobenzylidene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (112). The title compound was obtained as an orange solid (98 mg, 0.33 mmol, 33%) from 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (174 mg, 1.0 mmol) and 2-chlorobenzaldehyde (281 mg, 2.0 mmol 20.2, 118.9, 124.8, 126.0, 127.7, 128.8, 130.5, 130.9, 131.9, 132.6, 138.3, 139.4, 144.3, 150.7, 161.7 124.8, 126.7, 128.8, 129.6, 130.5, 134.0, 138.4, 144.46, 147.1, 150.9, 162. 4, 21.4, 119.2, 124.9, 127.5, 128.7, 128.8, 130.9, 132.9, 134.0, 134.3, 138.4, 138.5, 147.3, 150.9, 161.9 69.4, 118.4, 118.7, 120.1, 124.6, 126.8, 127.0, 128.0, 128.0, 128.5, 128.8, 129.7, 134.2, 136.6, 138 
(Z)-4-((3-Methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)methyl)benzonitrile (117).
The title compound was obtained as an orange solid (26 mg, 0.09 mmol, 18%) from 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (87 mg, 0.5 mmol) and 4-formylbenzonitrile (131 mg, 1.0 mmol 
(Z)-5-Methyl-4-(4-(methylsulfonyl)benzylidene)-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (118).

(Z)-4-(3-Hydroxybenzylidene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (119).
The title compound was obtained as an orange solid (22 mg, 0.08 mmol, 15%) from 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (87 mg, 0.5 mmol) and 3-hydroxybenzaldehyde (122 mg, 1.0 mM 123.6, 125.2, 128.9, 129.0, 130.0, 138.1, 139.5, 142.4, 150.4, 152.8, 154.3, 161.6 (Z)-3-(4-((6-Methoxy-4-oxo-4H-chromen-3-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (123). The title compound was obtained as an orange solid (57 mg, 0.08 mmol, 14%) from 3-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (130.9 mg, 0.6 mmol) and 6-methoxy-4-oxo-4H-chromene-3-carbaldehyde (183.8 mg, 0.9 mmol 
Ethyl (Z)-3-(3-methyl-5-oxo-4-(pyridin-4-ylmethylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoate (124).
The title compound was obtained as an orange solid (60 mg, 0.18 mmol, 18%) from ethyl 3-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoate (246 mg, 1.0 mmol) and isonicotinaldehyde (214 mg, 2.0 mmol).
1 H-NMR (400 MHz, CDCl 3 ) δ (ppm): 1.44 (t, J = 7.1 Hz, 3H), 2.41 (s, 3H), 4.43 (q, J = 7.1 Hz, 2H), 7.34 (s, 1H), 1H), 1H), 3H), 8.57 (s, 1H), 8.84 (d, J = 6.1 Hz, 2H) . 13 C-NMR (100 MHz, CDCl 3 ) δ (ppm): 13.3, 14.4, 61.2, 119.9, 123.0, 125.3, 126.2, 129.0, 131.3, 131.5, 138.1, 138.8, 143.3, 150.3, 150.6, 150.7, 161 8, 115.0, 117.8, 118.2, 121.4, 124.5, 128.9, 130.5, 138.3, 150.2, 150.5, 161.6 9, 119.7, 120.9, 122.4, 123.3, 124.6, 126.00, 129.0, 136.0, 137.1, 137.7, 146 (Z)-4-(4-Hydroxybenzylidene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (129). The title compound was obtained as an orange solid (20 mg, 0.07 mmol, 13%) from 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (87 mg, 0.5 mmol) and 4-hydroxybenzaldehyde (122 mg, 1.0 mmol). 13. 1, 115.8, 118.2, 122.6, 124.3, 123.9, 128.8, 137.40,138.4, 148.6, 151.8, 161.9, 163. 118.5, 124.9, 126.9, 127.3, 128.8, 128.9, 130.1, 134.0, 137.8, 139.3, 145.4, 147.8, 151.8 
